TxCell is developing regulatory T-cell therapies against autoimmune and inflammatory disorders using a novel CAR Treg technology platform.It is a subsidiary of Sangamo.
More TxCell content >Investment summary
TxCell has announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of €2.58 per share in cash, representing approximately 53% of the share capital and voting rights of TxCell. A further offer for the remaining shares is underway. Sangamo is a leading US biotech company and operates TxCell as a subsidiary. Sangamo intends to evaluate the potential of CAR-Treg therapies to prevent graft rejection in solid organ transplant and for the treatment of autoimmune diseases such as Crohn’s disease and multiple sclerosis, with trials from 2019. Sangamo intends to use its zinc finger nuclease gene-editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
---|---|---|---|---|---|---|
2016A | 0.0 | (11.9) | (12.7) | (97.5) | N/A | N/A |
2017A | 0.0 | (9.3) | (9.7) | (46.3) | N/A | N/A |
2018E | 0.0 | (11.8) | (11.9) | (53.0) | N/A | N/A |
2019E | 0.0 | (11.9) | (12.0) | (53.7) | N/A | N/A |
Content on TxCell
Sector |
---|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
---|---|
Forecast net debt (€m) | 12.2 |
Forecast gearing ratio (%) | 246 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
Key management |
|
---|---|
Stéphane Boissel | CEO |
Raphael Flipo | CFO |
You may also be interested in…
- Abliva
- AlzeCure Pharma
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- Cantargia
- Carmat
- Deinove
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- IRLAB Therapeutics
- Kiadis Pharma
- MagForce
- Medigene
- MOLOGEN
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- RhoVac
- Ryvu Therapeutics
- Scandion Oncology
- Sequana Medical
- Targovax
- Transgene
- Ultimovacs
- Vivesto
- Xbrane Biopharma